|8. Switch to an IL-17i biologic over tofacitinib (PICO 75)|Low (90â€“93, 105)|
|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy or in patients with concomitant IBD or a history of recurrent Candida infections.| |
|9. Switch to an IL-12/23i biologic over abatacept (PICO 71)|Low (99, 100, 103, 104)|